- Palisade Bio ( NASDAQ: PALI ) is trading 10% higher after it begun Phase 3 study evaluating its drug, LB1148, to help return bowel function in patients undergoing gastrointestinal surgery.
- The late-stage study will enroll about 600 patients.
- The primary endpoint of the study is time to recovery of the upper and lower gastrointestinal tract following surgery, which is defined as the time from the end of surgery to the toleration of food and first bowel movement.
For further details see:
Palisade Bio rises 10% after starting phase 3 study of gastrointestinal surgery therapy